News

Aurobindo Pharma has completed the transfer of the Company`s domestic branded generic pharmaceutical formulations products business, as a going concern to Auropharm with effect from 01 July 2026.

Aurobindo Pharma USA Inc., (APUSA), a wholly owned subsidiary of Aurobindo Pharma, announced the successful completion of its acquisition of Lannett Company, Inc., USA (Lannett), from Lannett Seller Holdco, Inc., following receipt of approval from the U.S. Federal Trade Commission on 18 June 2026. Effective 29 June 2026, Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC. The integration process will commence immediately, with a strong emphasis on ensuring uninterrupted access to critical medications, maintaining trusted relationships with partners, and supporting employees throughout the transition.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from 22 June 2026, to 26 June 2026. The inspection concluded with 2 observations and will be responded to within the stipulated time.

Aurobindo Pharma USA, Inc. (Aurobindo USA), a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026. Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition will significantly expand Aurobindo USA`s product offering in this segment while adding a U.S.-based manufacturing facility to its network. Lannett`s manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA`s domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.The transaction is expected to be immediately accretive to Aurobindo Group`s earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company`s portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.

Aurobindo Pharma announced that its wholly owned subsidiary, Aurobindo Pharma USA Inc. has received the approval from US Federal Trade Commission (FTC) for the acquisition of 100% of membership interest in Lannett Company LLC from LANNETT SELLER HOLDCO, INC.